LNTH vs. TEVA, ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, and BPMC
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.
Lantheus vs.
Lantheus (NASDAQ:LNTH) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, community ranking, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.
Lantheus has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Lantheus has a net margin of 28.57% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Lantheus' return on equity of 44.29% beat Teva Pharmaceutical Industries' return on equity.
Lantheus has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Teva Pharmaceutical Industries received 998 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.95% of users gave Teva Pharmaceutical Industries an outperform vote while only 66.15% of users gave Lantheus an outperform vote.
99.1% of Lantheus shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 1.5% of Lantheus shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Lantheus presently has a consensus price target of $132.67, suggesting a potential upside of 61.37%. Teva Pharmaceutical Industries has a consensus price target of $24.44, suggesting a potential upside of 38.57%. Given Lantheus' higher probable upside, equities research analysts clearly believe Lantheus is more favorable than Teva Pharmaceutical Industries.
In the previous week, Teva Pharmaceutical Industries had 6 more articles in the media than Lantheus. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 11 mentions for Lantheus. Lantheus' average media sentiment score of 0.82 beat Teva Pharmaceutical Industries' score of 0.26 indicating that Lantheus is being referred to more favorably in the media.
Summary
Lantheus beats Teva Pharmaceutical Industries on 11 of the 19 factors compared between the two stocks.
Get Lantheus News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantheus Competitors List
Related Companies and Tools
This page (NASDAQ:LNTH) was last updated on 6/10/2025 by MarketBeat.com Staff
Buy LNTH Stock Free LNTH Stock Alerts